Link to this page
Biological and Environmental Research Ontology
Last uploaded:
December 23, 2022
| Id | http://purl.obolibrary.org/obo/NCIT_C74061
http://purl.obolibrary.org/obo/NCIT_C74061
|
|---|---|
| Preferred Name | Crizotinib |
| Definitions |
An orally available aminopyridine-based inhibitor of the receptor tyrosine kinase anaplastic lymphoma kinase (ALK) and the c-Met/hepatocyte growth factor receptor (HGFR) with antineoplastic activity. Crizotinib, in an ATP-competitive manner, binds to and inhibits ALK kinase and ALK fusion proteins. In addition, crizotinib inhibits c-Met kinase, and disrupts the c-Met signaling pathway. Altogether, this agent inhibits tumor cell growth. ALK belongs to the insulin receptor superfamily and plays an important role in nervous system development. ALK dysregulation and gene rearrangements are associated with a series of tumors.
|
| Type | http://www.w3.org/2002/07/owl#Class |
All Properties
| definition | An orally available aminopyridine-based inhibitor of the receptor tyrosine kinase anaplastic lymphoma kinase (ALK) and the c-Met/hepatocyte growth factor receptor (HGFR) with antineoplastic activity. Crizotinib, in an ATP-competitive manner, binds to and inhibits ALK kinase and ALK fusion proteins. In addition, crizotinib inhibits c-Met kinase, and disrupts the c-Met signaling pathway. Altogether, this agent inhibits tumor cell growth. ALK belongs to the insulin receptor superfamily and plays an important role in nervous system development. ALK dysregulation and gene rearrangements are associated with a series of tumors. |
|---|---|
| prefLabel | Crizotinib
|
| label | Crizotinib
|
| CHEBI_ID | CHEBI:64310
|
| PDQ_Closed_Trial_Search_ID | 586080
|
| code | C74061
|
| Has_Target | |
| prefixIRI | NCIT:C74061
|
| in_subset |
See more
See less
|
| Display_Name | Crizotinib
|
| Preferred_Name | Crizotinib
|
| FDA_UNII_Code | 53AH36668S
|
| Contributing_Source |
CTRP
FDA
|
| Chemical_Formula | C21H22Cl2FN5O
|
| Maps_To | Crizotinib
|
| CAS_Registry | 877399-52-5
|
| NCI_Drug_Dictionary_ID | 586080
|
| Legacy Concept Name | MET_Tyrosine_Kinase_Inhibitor_PF-02341066
|
| type | |
| ALT_DEFINITION | A substance being studied in the treatment of some types of cancer. It blocks enzymes that cancer cells need to grow and spread. It may also prevent the growth of new blood vessels that tumors need to grow. It is a type of tyrosine kinase inhibitor and a type of antiangiogenesis agent.
|
| Is_Value_For_GDC_Property | |
| subClassOf | |
| PDQ_Open_Trial_Search_ID | 586080
|
| Accepted_Therapeutic_Use_For | Non-Small Cell Lung Cancer; inflammatory anaplastic lymphoma kinase (ALK)-positive myofibroblastic tumors (IMT).
|
| Semantic_Type | Pharmacologic Substance
|
| UMLS_CUI | C2974289
|
| Delete | Subject | Author | Type | Created |
|---|---|---|---|---|
| No notes to display |